Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Cantor Fitzgerald
Queensland Health
QuintilesIMS
Mallinckrodt
Express Scripts
Daiichi Sankyo
Dow
Federal Trade Commission

Generated: June 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021086

« Back to Dashboard

NDA 021086 describes ZYPREXA ZYDIS, which is a drug marketed by Lilly and is included in one NDA. It is available from one supplier. Additional details are available on the ZYPREXA ZYDIS profile page.

The generic ingredient in ZYPREXA ZYDIS is olanzapine. There are thirty-three drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the olanzapine profile page.
Summary for 021086
Tradename:ZYPREXA ZYDIS
Applicant:Lilly
Ingredient:olanzapine
Patents:0
Therapeutic Class:Antipsychotics
Bipolar Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 021086
Suppliers and Packaging for NDA: 021086
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZYPREXA ZYDIS olanzapine TABLET, ORALLY DISINTEGRATING;ORAL 021086 NDA Eli Lilly and Company 0002-4453 N 0002-4453-85
ZYPREXA ZYDIS olanzapine TABLET, ORALLY DISINTEGRATING;ORAL 021086 NDA Eli Lilly and Company 0002-4454 N 0002-4454-85

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrength5MG
Approval Date:Apr 6, 2000TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrength10MG
Approval Date:Apr 6, 2000TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrength15MG
Approval Date:Apr 6, 2000TE:ABRLD:Yes

Expired US Patents for NDA 021086

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly ZYPREXA ZYDIS olanzapine TABLET, ORALLY DISINTEGRATING;ORAL 021086-001 Apr 6, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Lilly ZYPREXA ZYDIS olanzapine TABLET, ORALLY DISINTEGRATING;ORAL 021086-003 Apr 6, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Lilly ZYPREXA ZYDIS olanzapine TABLET, ORALLY DISINTEGRATING;ORAL 021086-003 Apr 6, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Lilly ZYPREXA ZYDIS olanzapine TABLET, ORALLY DISINTEGRATING;ORAL 021086-003 Apr 6, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
AstraZeneca
Covington
Boehringer Ingelheim
US Army
Medtronic
Farmers Insurance
Accenture
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.